Diabetes Device vs. Mortgage: A Life-Saving Choice

Sai Akunuri's health is compromised as he prioritizes paying his mortgage over his life-saving continuous glucose monitor (CGM). The device is crucial for managing his insulin-dependent type 2 diabetes, preventing dangerous hypoglycaemic episodes that can lead to paralysis. He previously experienced a severe episode that left him unable to move.

Managing diabetes requires frequent finger pricks, adding strain to Akunuri's life, who works two jobs. The cost of CGMs is a significant barrier for individuals with type 2, type 3c, and gestational diabetes, as they are not subsidised and can cost thousands annually. In contrast, those with type 1 diabetes have access to subsidised devices.

Diabetes Australia advocates for expanded CGM subsidies to include high-priority groups, noting the technology's life-changing impact. While acknowledging fiscal constraints, they emphasize CGMs are a necessity. A federal government spokesperson affirmed a commitment to supporting Australians with diabetes.

Studies suggest wider CGM access could improve patient outcomes and significantly reduce healthcare expenditures. Diabetes-related complications currently cost the Australian healthcare system approximately $7.3 billion each year. Recommendations from a 2024 diabetes inquiry propose subsidising CGMs for a much larger population.